canyon landscape

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with early Parkinson’s disease (PD) who are on stable symptomatic PD medication.


The purpose of this study is to compare the effects of prasinezumab vs placebo on patients with early Parkinson’s disease who are taking standard medication to manage their disease symptoms.

Who Can Participate

Patient ages 50-85 with a diagnosis of PD for at least 6 months to maximum of 3 years at screening. Currently taking a monotherapy treatment with MAO-B inhibitors daily or up to 450 L-Dopa for at least 6 months, with stable doses for 3 months prior to baseline. No fluctuations or dyskinesia. H&Y <=2


Participants can expect to have up to 30 visits within 76 weeks.

Open and enrolling subjects.
Phoenix, Arizona
Total Participants
Primary Sponsor
Hoffmann-La Roche